Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Payables (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Payables for 3 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Payables rose 474.27% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, up 474.27% year-over-year, with the annual reading at $2.0 million for FY2025, 474.27% up from the prior year.
  • Payables hit $2.0 million in Q4 2025 for Connect Biopharma Holdings, down from $2.0 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $2.3 million in Q2 2025 to a low of $342000.0 in Q4 2024.
  • Historically, Payables has averaged $1.6 million across 3 years, with a median of $2.0 million in 2025.
  • Biggest five-year swings in Payables: tumbled 84.52% in 2024 and later skyrocketed 474.27% in 2025.
  • Year by year, Payables stood at $2.2 million in 2023, then crashed by 84.52% to $342000.0 in 2024, then surged by 474.27% to $2.0 million in 2025.
  • Business Quant data shows Payables for CNTB at $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.3 million in Q2 2025.